Cadila Q3 PAT may dip 29.7% YoY to Rs. 382 cr: Sharekhan

Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.

Sharekhan has come out with its third quarter (October-December’ 18) earnings estimates for the Pharma sector. The brokerage house expects Cadila to report net profit at Rs. 382 crore down 29.7% year-on-year (down 8.6% quarter-on-quarter).

Net Sales are expected to decrease by 6.7 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 3,043 crore, according to Sharekhan.

TWO DAYS FREE TRIALS AND BEST SERVICE PACKAGES  FOR DEALING IN STOCK MARKET. CLICK HERE >>  Option Trading Tips OR ONE MISSED CALL ON @9644405056